Skip to content

Study · Animal study (in vivo) · rat · 2019

7 results

Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.

Badawi GA, Abd El Fattah MA, Zaki HF, El Sayed MI

Neurotoxicity research23 Jan 2019Cited by 44 (Europe PMC)

PMID30673988 (opens in a new tab)DOI10.1007/s12640-019-9998-3 (opens in a new tab)PepBankPUB-30673988
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rotenone-lesioned rats, liraglutide markedly attenuated L-dopa-induced dyskinesia scores.

    In plain wordsIn rats with a Parkinson's disease model, liraglutide reduced movement side effects caused by L-dopa.

    Peptide
    Liraglutide
    Outcome
    DecreaseL-dopa-induced dyskinesia score
    Study

    ratn: not reported in source

    Rotenone-lesioned rat model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    50 μg/kg · subcutaneous · 16 daysAs given in this study (rat).

    Source sentences

    Summary
    Sitagliptin and liraglutide revealed marked attenuation of LID scores
    2 context sentences
    Summary · context
    Rats were injected with rotenone (3 mg/kg/day, s.c.) for 10 consecutive days to induce the experimental PD.
    Summary · context
    The rotenone-treated rats were administered sitagliptin (30 mg/kg/day, p.o.) and liraglutide (50 μg/kg, s.c.) for 16 days either alone or together with L-dopa/carbidopa (50/25 mg/kg/day, i.p.).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rotenone-lesioned rats, liraglutide markedly increased motor performance.

    In plain wordsIn rats with a Parkinson's disease model, liraglutide improved movement performance.

    Peptide
    Liraglutide
    Outcome
    IncreaseMotor performance in open-field test
    Study

    ratn: not reported in source

    Rotenone-lesioned rat model of Parkinson's disease
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    50 μg/kg · subcutaneous · 16 daysAs given in this study (rat).

    Source sentences

    Summary
    in addition, they markedly increased animals' motor performance.
    2 context sentences
    Summary · context
    Rats were injected with rotenone (3 mg/kg/day, s.c.) for 10 consecutive days to induce the experimental PD.
    Summary · context
    The rotenone-treated rats were administered sitagliptin (30 mg/kg/day, p.o.) and liraglutide (50 μg/kg, s.c.) for 16 days either alone or together with L-dopa/carbidopa (50/25 mg/kg/day, i.p.).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rotenone-lesioned rats, liraglutide preserved tyrosine hydroxylase and VMAT2-positive cells in the substantia nigra pars compacta.

    In plain wordsIn rats with a Parkinson's disease model, liraglutide protected dopamine-related nerve cells in the brain.

    Peptide
    Liraglutide
    Outcome
    IncreaseTyrosine hydroxylase and VMAT2-positive cells in SNpc
    Study

    ratn: not reported in source

    Rotenone-lesioned rat model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    50 μg/kg · subcutaneous · 16 daysAs given in this study (rat).

    Source sentences

    Summary
    Moreover, they preserved substantia nigra pars compacta (SNpc) tyrosine hydroxylase (TH) and vesicular monoamine transporter 2-positive (VMAT2) cells with prominent increase of the striatal dopamine (DA) content.
    2 context sentences
    Summary · context
    Rats were injected with rotenone (3 mg/kg/day, s.c.) for 10 consecutive days to induce the experimental PD.
    Summary · context
    The rotenone-treated rats were administered sitagliptin (30 mg/kg/day, p.o.) and liraglutide (50 μg/kg, s.c.) for 16 days either alone or together with L-dopa/carbidopa (50/25 mg/kg/day, i.p.).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rotenone-lesioned rats, liraglutide increased striatal dopamine content.

    In plain wordsIn rats with a Parkinson's disease model, liraglutide raised dopamine levels in a movement-related brain region.

    Peptide
    Liraglutide
    Outcome
    IncreaseStriatal dopamine content
    Study

    ratn: not reported in source

    Rotenone-lesioned rat model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    50 μg/kg · subcutaneous · 16 daysAs given in this study (rat).

    Source sentences

    Summary
    Moreover, they preserved substantia nigra pars compacta (SNpc) tyrosine hydroxylase (TH) and vesicular monoamine transporter 2-positive (VMAT2) cells with prominent increase of the striatal dopamine (DA) content.
    2 context sentences
    Summary · context
    Rats were injected with rotenone (3 mg/kg/day, s.c.) for 10 consecutive days to induce the experimental PD.
    Summary · context
    The rotenone-treated rats were administered sitagliptin (30 mg/kg/day, p.o.) and liraglutide (50 μg/kg, s.c.) for 16 days either alone or together with L-dopa/carbidopa (50/25 mg/kg/day, i.p.).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rotenone-lesioned rats, liraglutide significantly decreased nigral neuromelanin-positive cells.

    In plain wordsIn rats with a Parkinson's disease model, liraglutide reduced neuromelanin-positive cells in the brain.

    Peptide
    Liraglutide
    Outcome
    DecreaseNigral neuromelanin-positive cells
    Study

    ratn: not reported in source

    Rotenone-lesioned rat model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    50 μg/kg · subcutaneous · 16 daysAs given in this study (rat).

    Source sentences

    Summary
    On the other hand, they significantly decreased nigral neuromelanin (NM)-positive cells, activated microglia, gliosis, and other pathological changes.
    2 context sentences
    Summary · context
    Rats were injected with rotenone (3 mg/kg/day, s.c.) for 10 consecutive days to induce the experimental PD.
    Summary · context
    The rotenone-treated rats were administered sitagliptin (30 mg/kg/day, p.o.) and liraglutide (50 μg/kg, s.c.) for 16 days either alone or together with L-dopa/carbidopa (50/25 mg/kg/day, i.p.).
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rotenone-lesioned rats, liraglutide significantly decreased activated microglia.

    In plain wordsIn rats with a Parkinson's disease model, liraglutide reduced activated immune cells in the brain.

    Peptide
    Liraglutide
    Outcome
    DecreaseActivated microglia
    Study

    ratn: not reported in source

    Rotenone-lesioned rat model of Parkinson's disease
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    50 μg/kg · subcutaneous · 16 daysAs given in this study (rat).

    Source sentences

    Summary
    On the other hand, they significantly decreased nigral neuromelanin (NM)-positive cells, activated microglia, gliosis, and other pathological changes.
    2 context sentences
    Summary · context
    Rats were injected with rotenone (3 mg/kg/day, s.c.) for 10 consecutive days to induce the experimental PD.
    Summary · context
    The rotenone-treated rats were administered sitagliptin (30 mg/kg/day, p.o.) and liraglutide (50 μg/kg, s.c.) for 16 days either alone or together with L-dopa/carbidopa (50/25 mg/kg/day, i.p.).
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rotenone-lesioned rats, liraglutide significantly decreased gliosis.

    In plain wordsIn rats with a Parkinson's disease model, liraglutide reduced scarring-like changes in brain support cells.

    Peptide
    Liraglutide
    Outcome
    DecreaseGliosis
    Study

    ratn: not reported in source

    Rotenone-lesioned rat model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    50 μg/kg · subcutaneous · 16 daysAs given in this study (rat).

    Source sentences

    Summary
    On the other hand, they significantly decreased nigral neuromelanin (NM)-positive cells, activated microglia, gliosis, and other pathological changes.
    2 context sentences
    Summary · context
    Rats were injected with rotenone (3 mg/kg/day, s.c.) for 10 consecutive days to induce the experimental PD.
    Summary · context
    The rotenone-treated rats were administered sitagliptin (30 mg/kg/day, p.o.) and liraglutide (50 μg/kg, s.c.) for 16 days either alone or together with L-dopa/carbidopa (50/25 mg/kg/day, i.p.).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.